Renovorx Inc (RNXT) Stock Price, Quote & News

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 284 4433

Fax: 650 397 4433

Website: renovorx.com

Address:

2570 West El Camino Real, Suite 320, Mountain View, United States

OfficialStocktwitsUser Feb. 4 at 12:01 AM

$RNXT RSI: 45.94, MACD: 0.0099 Vol: 0.06, MA20: 1.02, MA50: 0.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

bowlerhatsftw Jan. 31 at 10:35 PM

$RNXT 1/31/26

2 · Reply

victory369 Jan. 30 at 8:57 PM

$RNXT

0 · Reply

victory369 Jan. 30 at 8:08 PM

$RNXT I’m in 🚀

1 · Reply

brandonscience Jan. 30 at 5:46 PM

$RNXT — Orin Hirschman (AIGH) disclosed ~7.1% ownership via 13G. Known for investing in capital hungry microcap biotechs with asymmetric upside. Not a pumper, but not a miracle worker either. Passive filing = no control play. Neutral-to-mildly bullish signal to me.

1 · Reply

Rnxtsavior Jan. 30 at 2:48 PM

$RNXT So what's it going to be? Another little light volume up big volume down typical move? Which from under a buck start could take it to low .80's or worse... or do they let it back over a buck?

0 · Reply

GJ_Rockabilt Jan. 30 at 1:01 PM

$RNXT Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

Purple_Tip_Capital Jan. 29 at 2:54 PM

$RNXT this doesn’t seem good for us

1 · Reply

Rnxtsavior Jan. 28 at 6:47 PM

$RNXT Wow... what a jump on the news. You know what happens every time??? Selling will start. This pig is exhausted. .80's then .70's. Then... we have to unfortunately reverse split. It's all coming.

0 · Reply

Mortz20 Jan. 28 at 4:34 PM

$RNXT “This translational study not only aims to validate a practical, real-time method for intra-arterial pressure monitoring during TAMP procedures using RenovoCath, but also may reinforce the potential for individualized, optimized drug-delivery with our proprietary technology,” said Dr. Ramtin Agah, RenovoRx’s Chairman and Chief Medical Officer and co-author of the study. “We are excited to present the full data with Dr. Laing at the SIO 2026 Meeting as we continue to demonstrate the potential benefits of our therapy platform to the marketplace.” Imma say Feb 6, 5:45-6 ET will be a good listen and watch for the study details. Money is coming brothers and sisters. Buy, buy, buy and wait!

0 · Reply

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Jan 20, 2026, 8:30 AM EST - 14 days ago

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Jan 14, 2026, 8:30 AM EST - 20 days ago

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

Jan 8, 2026, 8:30 AM EST - 26 days ago

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

Dec 11, 2025, 8:30 AM EST - 7 weeks ago

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Dec 9, 2025, 2:57 PM EST - 2 months ago

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

Dec 1, 2025, 8:30 AM EST - 2 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Nov 19, 2025, 8:30 AM EST - 2 months ago

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Nov 13, 2025, 4:05 PM EST - 2 months ago

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 6, 2025, 8:30 AM EST - 3 months ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 4, 2025, 8:30 AM EST - 3 months ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Oct 27, 2025, 8:30 AM EDT - 3 months ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 9, 2025, 8:30 AM EDT - 4 months ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Sep 25, 2025, 8:30 AM EDT - 4 months ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 11, 2025, 8:30 AM EDT - 5 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Aug 20, 2025, 8:30 AM EDT - 5 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 14, 2025, 4:05 PM EDT - 6 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 6, 2025, 8:30 AM EDT - 6 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Jul 28, 2025, 8:30 AM EDT - 6 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 14, 2025, 8:30 AM EDT - 7 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

May 15, 2025, 9:07 PM EDT - 9 months ago

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:05 PM EDT - 9 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 8:30 AM EDT - 9 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 6, 2025, 8:30 AM EDT - 9 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 1, 2025, 8:30 AM EDT - 9 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Apr 29, 2025, 8:30 AM EDT - 10 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 16, 2025, 8:30 AM EDT - 10 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 4, 2025, 8:30 AM EDT - 10 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 1, 2025, 8:30 AM EDT - 11 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Mar 28, 2025, 8:00 AM EDT - 11 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 26, 2025, 8:00 AM EDT - 11 months ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 20, 2025, 8:00 AM EDT - 11 months ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 19, 2025, 8:00 AM EDT - 11 months ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Feb 26, 2025, 8:00 AM EST - 1 year ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 13, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 11, 2025, 7:00 AM EST - 1 year ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 1 year ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 4:05 PM EST - 1 year ago

RenovoRx Announces Proposed Public Offering

Feb 5, 2025, 2:14 AM EST - 1 year ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Jan 27, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Dec 30, 2024, 8:00 AM EST - 1 year ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Nov 20, 2024, 8:45 AM EST - 1 year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 14, 2024, 8:00 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Sep 25, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Aug 27, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 14, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Jul 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Jun 26, 2024, 8:30 AM EDT - 1 year ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

OfficialStocktwitsUser Feb. 4 at 12:01 AM

0 · Reply

bowlerhatsftw Jan. 31 at 10:35 PM

$RNXT 1/31/26

2 · Reply

victory369 Jan. 30 at 8:57 PM

$RNXT

0 · Reply

victory369 Jan. 30 at 8:08 PM

$RNXT I’m in 🚀

1 · Reply

brandonscience Jan. 30 at 5:46 PM

1 · Reply

Rnxtsavior Jan. 30 at 2:48 PM

$RNXT So what's it going to be? Another little light volume up big volume down typical move? Which from under a buck start could take it to low .80's or worse... or do they let it back over a buck?

0 · Reply

GJ_Rockabilt Jan. 30 at 1:01 PM

$RNXT Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

Purple_Tip_Capital Jan. 29 at 2:54 PM

$RNXT this doesn’t seem good for us

1 · Reply

Rnxtsavior Jan. 28 at 6:47 PM

$RNXT Wow... what a jump on the news. You know what happens every time??? Selling will start. This pig is exhausted. .80's then .70's. Then... we have to unfortunately reverse split. It's all coming.

0 · Reply

Mortz20 Jan. 28 at 4:34 PM

0 · Reply

victory369 Jan. 28 at 4:34 PM

$RNXT Lets go 😁💥🚀

0 · Reply

victory369 Jan. 28 at 2:25 PM

$RNXT Lets go 😁💥🚀

0 · Reply

victory369 Jan. 28 at 1:39 PM

$RNXT Let drop the damn PR 🥹 Don’t be quiet like this

1 · Reply

Mortz20 Jan. 28 at 1:12 PM

$RNXT I’m not 100% but I have a feeling yesterday’s dump was due to the bomb Trump dropped on Medi Care. Healthcare sector in general was slaughtered yesterday.

0 · Reply

victory369 Jan. 28 at 11:56 AM

$RNXT What the heck wrong with this stock ? why very quiet ? is this company dead ? 😁

0 · Reply

Rnxtsavior Jan. 27 at 6:17 PM

$RNXT .89. Drifting down to the reverse split zone. Sheeny man will explain how it's not companies fault need to do it to be compliant. They need to do it to get new bigger suckers.

0 · Reply

brandonscience Jan. 27 at 3:15 PM

$RNXT Smells like ATM to me...

1 · Reply

Rnxtsavior Jan. 26 at 10:57 PM

$RNXT 50,000 dump after hours at .92. News

0 · Reply

Rnxtsavior Jan. 26 at 8:59 PM

$RNXT Don't know why everyone gets so mad at me. I'm the wrong person you should be mad at. I also promise not to say "I told you so" coming soo er than you think. 10 for 1 or 20 for 1 is the question.

1 · Reply

Rnxtsavior Jan. 26 at 4:39 PM

$RNXT About 80k slow in last 15 minutes. Someone getting out... why? With all great (bs) news coming? Only thing coming in my opinion is reverse split news

1 · Reply

AZOZ Jan. 22 at 2:06 PM

$MIGI $CABA $UUU $RNXT Insider's love it right now!

0 · Reply

Rnxtsavior Jan. 21 at 9:28 PM

$RNXT Didn't make compliance. Have to start over. Reverse split coming soon.

1 · Reply

Market Cap	38.12M
Revenue (ttm)	40,000.00
Net Income (ttm)	-8.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-22,025.00%
Debt to Equity Ratio	0.00

Volume	116,600
Avg Vol	265,850
Day's Range	N/A - N/A
Shares Out	36.65M
Stochastic %K	67%
Beta	1.31
Analysts	Strong Sell
Price Target	$5.62